Justin Klein
Partner @ New Enterprise Associates
Washington, United States
Justin Klein is a Series B investor at New Enterprise Associates in Washington focused on Health Care and Medical Device. Justin Klein is based out of McLean, Virginia and is the Co-Founder & Managing Partner of Vensana Capital. Justin previously worked at New Enterprise Associates as a Partner. Justin Klein attended the Duke University.
- Total investments:
- 30
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries Justin Klein invests in
Stages Justin Klein invests in
Countries Justin Klein invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 12 (40%)
- Medical Device 10 (33%)
- Biotechnology 8 (27%)
- Medical 7 (23%)
- Wellness 3 (10%)
Stage
- Series B 7 (23%)
- Series C 7 (23%)
- Series A 6 (20%)
- Series D 2 (7%)
- Venture - Series Unknown 2 (7%)
Country
- United States 15 (50%)
- France 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ventaris Surgical is a medical equipment company that provides surgical instruments to specialists. | $30.7M / Series A / Jan 09, 2026 | ||
| Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training,and even real-time decision-making.Apella was founded in 2019 and is headquartered in San Francisco, California. | $80M / Series B / Jan 07, 2026 | ||
| Luna Diabetes is a manufacturer of medical equipment. | $23.6M / Series A / Aug 18, 2025 | ||
| Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular. | Series B / Mar 25, 2025 | ||
| Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular. | $35M / Series A / Oct 17, 2023 | ||
| Volta Medical is an innovative start-up with headquarters in Marseille (France). Volta aims at developing a wide range of intelligent software solutions designed to guide cardiologists during interventional procedures. The company was founded in 2016 with a focus on atrial fibrillation, the most common cardiac arrhythmia. Volta’s first productsindeed provide assistance to interventional cardiologists who operate on patients with atrial fibrillation. The first product embodies top-tier expertise in interventional cardiology and intracardiac signal analysis. The company relies on artificial intelligence approaches to gain insight into innovative therapies. Today, Volta is committed to recruit top talents to further advance Volta’s technology and products. Volta is ideally positioned to offer unique work opportunities while respecting the fundamentals of reasonable work hours and diversity. As a testimony to our ambition, our technology has been granted a “Seal of Excellence” by the European Commission. | $37.9M / Series B / Jan 05, 2023 | ||
| Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway.Throughthese data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks. | $223M / Series C / Jul 25, 2022 | ||
| Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training,and even real-time decision-making.Apella was founded in 2019 and is headquartered in San Francisco, California. | $21M / Series A / Dec 20, 2021 | ||
| Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway.Throughthese data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks. | $43M / Series B / Jun 21, 2021 | ||
| GPB Scientific is a biotechnology company that markets its technology to life sciences companies and research establishments. The company has accumulated an extensive portfolio of patents and know-how utilizing microchip technology for size-based enrichment and/or for affinity-based cell capture.The company was founded in 2002 andheadquartered in Richmond, Virginia. | $18M / Venture - Series Unknown / May 27, 2021 | ||
| See all 30 investments → | |||
Co-Investors
New Enterprise Associates is a venture capital firm that invests in technology and healthcare startups. The firm engages with entrepreneurs at various stages of business development, providing support from initial funding to public offerings. The company focuses on the technology and healthcare industries.
New Enterprise Associates Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Sharata
Associate
|
|||
Anthony Florence
General Partner
|
|||
Bala Deshpande
Sr. Managing Director, India
|
|||
Hilarie Koplow-McAdams
Venture Partner
|
|||
Jay Graf
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Justin Klein invest in?
Justin Klein invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Series B and Series C stage. Most of the 30 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Justin Klein?
Public channels for Justin Klein include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Justin Klein last invest?
The most recent investment recorded for Justin Klein closed in Jan 2026. Shizune tracks 30 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
